An estimated 20–25% of the population is affected by chronic, non-communicable
inflammatory skin diseases. Chronic skin inflammation has many causes. Among the most …

Dermatomyositis (DM) is an idiopathic inflammatory myopathy that is clinically
heterogeneous and that can be difficult to diagnose. Cutaneous manifestations sometimes …

Dermatomyositis is a rare inflammatory disease with characteristic cutaneous findings and
varying amounts of systemic involvement. Patients may present with skin disease alone …

Objective To identify clinical and serologic correlates of cutaneous ulcers in dermatomyositis
(DM). Methods We retrospectively examined a cohort of 152 DM patients. We compared the …

Background Dermatomyositis (DM) is an autoimmune disease primarily affecting skin and
muscle. Objectives The purpose of this study was to determine whether an association exists …

Background Treatment options are limited for skin disease in dermatomyositis. Lenabasum
is a cannabinoid receptor type 2 agonist that triggers the resolution of inflammation …

Background Facial port-wine stains (PWS) are considered by some an aesthetic skin
problem, yet impact on quality of life (QoL) has not been objectively documented. Objective …

Summary Background Interleukin (IL)‐31 is implicated in pruritus associated with pruritic
skin diseases like atopic dermatitis. Although pruritus is a prominent feature in …

Summary Background The Cutaneous Dermatomyositis Disease Area and Severity Index
(CDASI) was developed for use in clinical trials and longitudinal patient assessment …

Background Lenabasum is a cannabinoid type 2 receptor (CB2R) reverse agonist that
demonstrates anti-inflammatory effects in vivo and in vitro in dermatomyositis (DM) and is …